MOLN

2.5255.25%
WM

William M. Burns

Independent Chairman of the Board

Mr. William M. Burns, BA also known as Bill, serves as the Member of Senior Adviser Board at HealthCare Royalty Management LLC. He has been a member of HCRx’s SAB since 2020. He is Member of Scientific Advisory Board of Nxera Pharma Co. Ltd. from 2025. He has been the Chairman of the Board at Molecular Partners AG since April 18, 2018 and has been its Director since October 31, 2017. Mr. Burns served as an Advisor, Partner and Business & Scientific Advisor of BioMedPartners AG until 2024. Mr. Burns served as the Chief Executive Officer of Pharmaceuticals Division at Hoffmann-La Roche Inc. from 2005 to 2009. He held various executive positions at Roche for several years. He has extensive experience in Biotechnology. Mr. Burns served as the Head of the Pharmaceuticals Division at Hoffmann-La Roche Inc. He served as the Chief Executive Officer of Pharmaceuticals Division at Roche Holding AG from January 2004 to December 31, 2009. For many years, Mr. Burns worked for Roche. He served as the Head of the Pharmaceuticals Division at Roche Holding AG from 2001 to December 15, 2004. From 1998 to 2001, Mr. Burns served as the Head of Europe and International Business of Roche Pharmaceuticals. From 1991 to 1998, he served as a Global Head of Strategic Marketing and Business Development at Roche Pharmaceuticals. He was Chief Executive Officer of Roche Pharmaceuticals from 2001 to 2009, when he joined the Board of Directors of F. Hoffmann-La Roche Ltd. until he retired in 2014. Mr. Burns joined Beecham Pharmaceuticals in 1969 and as its Management Trainee. He worked for years with Beecham in a variety of roles of increasing responsibility. Mr. Burns worked for Roche from 1986 until 2009. Mr. Burns served as a Director of Sales and Marketing at Roche since 1986 and its Head of Pharmaceuticals Division since 1988. Mr. Burns served as the Global Head of Strategic Marketing and Business Development of Hoffmann-La Roche Inc., since 1991 and Head of Europe/International since 1998. He was responsible for Global Business Development and Strategic Marketing. His responsibilities also included all international commercial operations. During his time with Roche, Mr. Burns had significant involvement in the privatization of Genentech, the integration of Boehringer Mannheim and the negotiations that resulted in Roche becoming a majority owner of Chugai. He has built a distinguished track record in the pharmaceutical industry over the years. He has pharmaceutical, healthcare, industry, leadership and management expertise. He serves as the Chairman of Masters Pharmaceuticals. Mr. Burns has been the Chairman and Director of Okairos AG since September 14, 2011. Mr. Burns served as the Chairman of Biotie Therapies Corp., since April 3, 2014 until May 11, 2016. He served as the Chairman of Interpharma. He serves as a Head of International Advisory Board at ePatient Network Limited. He served as Vice Chairman of Molecular Partners AG since October 31, 2017 until April 18, 2018. He was Independent Non-Executive Vice Chairman of Mesoblast Limited since 2016 until November 11, 2026. He serves as a Vice Chairman of Vestergaard Frandsen S.A. and Non-Executive Chairman of the Board of Vestergaard Holding. He served as the Deputy Chairman of Biotie Therapies Corp., from March 29, 2012 to April 2014. Mr. Burns serves as Member of the International Advisory Council at Chugai Pharmaceutical Co., Ltd. He served as an Independent Non-Executive Director of Shire plc from March 15, 2010 to April 24, 2018 and as its Senior Independent Non-Executive Director from April 28, 2016 to April 24, 2018. Mr. Burns brought to the Board extensive international R&D, commercial, business development and operational experience in the pharmaceutical sector. He served as a Director of Biotie Therapies Corp., since February 7, 2011 until May 11, 2016. He is a Director at Crucell. In 2014, he was appointed a Trustee of the Institute of Cancer Research and in 2016 a Governor of The Wellcome Trust. He served as Board Governor at Wellcome Trust Finance plc. He serves as a Member of Advisory Board of Epidarex Capital. Mr. Burns serves as Non-Executive Director of Biotie Therapeutics. He was Independent Non-Executive Director of Mesoblast Limited since March 06, 2014 until November 11, 2026. He serves as a Non-Executive Director of Mesoblast, Inc. Mr. Burns serves as a Member of the Scientific Advisory Board of the University of Cologne/Bonn Center for Integrated Oncology. He served as a Member of Supervisory Board at Crucell N.V., since June 2010. He served as a Non-Executive Director of Chugai Pharmaceutical Co. Ltd., from 2002 to March 27, 2014. He serves as a Director of Genentech, Inc. since April 2004. He served as a Non-Executive Director of Roche Holding AG since March 2, 2010. He serves as a Member of the Novo Holdings Advisory Group. Mr. Burns holds a Bachelor's degree in Economics from the University of Strathclyde.

Positions